James Sabatowski is a seasoned pharmaceutical scientist and manager with over 25 years of extensive experience in analytical chemistry, product development, and manufacturing quality control. As the Director of Analytical Chemistry at Eli Lilly and Company, he plays a pivotal role in advancing the company's...
James Sabatowski is a seasoned pharmaceutical scientist and manager with over 25 years of extensive experience in analytical chemistry, product development, and manufacturing quality control. As the Director of Analytical Chemistry at Eli Lilly and Company, he plays a pivotal role in advancing the company's capabilities in the rapidly evolving landscape of drug development, particularly focusing on innovative modalities such as siRNA-based therapeutics.
In his current role, James provides critical analytical chemistry expertise and leadership for Global Analytical Services, ensuring that Eli Lilly remains at the forefront of biopharmaceutical innovation. He collaborates closely with Research and Development teams to establish robust capabilities and control strategies for siRNA drug products, which are essential for the development of next-generation therapeutics. His work encompasses the development and improvement of analytical methods aimed at facilitating the commercialization of these complex biologic products.
James is also instrumental in addressing the challenges posed by nitrosamine impurities in drug substances, leveraging his deep knowledge of LC/MS/MS techniques to ensure compliance with stringent regulatory requirements. His expertise in visual inspection, technical transfers, and quality systems further enhances the reliability and safety of Eli Lilly's drug products. With a strong foundation in organic chemistry and a commitment to GMP standards, James is dedicated to fostering a culture of excellence and innovation within his team, driving forward the mission of delivering high-quality medicines to patients worldwide.
